Articles by Cynthia Challener, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Cynthia Challener, PhD

Advances in UPLC Techniques and Column Chemistry Aid the Confirmation of Biosimilarity

Automated sample handling, advanced glycan analysis and specially designed columns are helping biosimilar manufacturers speed up confirmation of the biosimilarity of their products.
Feb 2, 2014

Automated sample handling, advanced glycan analysis, and specially designed columns are help speed up confirmation of the biosimilarity.

More Rapid Extractable & Leachable Analyses with Advanced Mass Spectrometers

Advances in technology are improving the sensitivity and accuracy of mass spectrometry increasing its use for the analysis of extractables and leachables.
Feb 2, 2014

Advances in technology are improving the sensitivity and accuracy of mass spectrometry, increasing its use for the analysis of extractables and leachables.

Advanced triple quadrupole technology for improved performance and ease of use

Advanced triple quadrupole technology for improved performance and ease of use.
Feb 2, 2014

Advanced triple quadrupole technology for improved performance and ease of use.

Simple and affordable mass detection for the chromatographer

Simple and affordable mass detection for the chromatographer.
Feb 2, 2014

Simple and affordable mass detection for the chromatographer.

Will CMOs Provide Sufficient Capacity for Growing Biologics Demand

Jan 31, 2014

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

The Role of NMR and Mass Spectroscopy in Glycan Analysis

NMR analysis provides crucial structural information of synthesized glycans while LC-MS/MS is ideal for quantitation of free sugars in biological matrices.
Jan 2, 2014

NMR analysis provides crucial structural information of synthesized glycans while LC-MS/MS is ideal for quantitation of free sugars in biological matrices.

Evaporative Light Scattering Seeing Increased Use as Detector for Nonchromophoric Compounds

Difficult samples, including carbohydrates, triglycerides, lipids, phospolipids, underivatized fatty and amino acids, and modified peptides can be detected with high sensitivity and accuracy.
Dec 11, 2013

Difficult samples, including carbohydrates, triglycerides, lipids, phospolipids, underivatized fatty and amino acids, and modified peptides can be detected with high sensitivity and accuracy.

Novel Host Cell Line Targets Potential Sources of Immunogenicity in Chinese Hamster Ovary Cells

A novel host cell line trait stacked with knockouts of the CMAH and GGTA1 gene sequences is designed to produce safer therapeutic proteins.
Dec 11, 2013

A novel host cell line trait stacked with knockouts of the CMAH and GGTA1 gene sequences is designed to produce safer therapeutic proteins.

Novartis' US Influenza Cell-Culture Facility Recognized

For its use of innovative technology for the production of seasonal and pandemic influenza vaccines, the Novartis Holly Springs, North Carolina facility was the Overall Winner of the 2013 Facility of the Year Award issued by the International Society for Pharmaceutical Engineering (ISPE).
Dec 4, 2013

For its use of innovative technology for the production of seasonal and pandemic influenza vaccines, the Novartis Holly Springs, North Carolina facility was the Overall Winner of the 2013 Facility of the Year Award issued by the International Society for Pharmaceutical Engineering (ISPE).

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here